Navigation Links
NYU Cancer Institute researcher among first NIH EUREKA award recipients

New York City, NY September 3, 2008 - The National Institutes of Health (NIH) has awarded $42.2 million to fund 38 exceptionally innovative research projects that could have an extraordinarily significant impact on many areas of science. The grants, from a new program called EUREKA (for Exceptional, Unconventional Research Enabling Knowledge Acceleration), targets investigators who are testing novel, unconventional hypotheses or are pursuing major methodological or technical advances. Eureka researchers will receive direct costs of approximately $200,000 per year for up to four years.

Michelle Krogsgaard, Ph.D, assistant professor of pathology at the NYU Cancer Institute, is the first NYU School of Medicine recipient of the EUREKA award. In 2006, Dr. Krogsgaard joined NYU and her work has focused on the different signaling methods T-cells use in the contexts of cancer and autoimmune disease. The EUREKA award will allow Dr. Krogsgaard to explore the complex molecular mechanisms that govern the training and activation of immune cells; specifically, how intracellular signals are generated in T-cells, currently an immunological black box. Dr. Krogsgaard practices an interdisciplinary approach to her research, which incorporates cellular, chemical and structural biology techniques. Through this fresh perspective and multidisciplinary approach, Dr. Krogsgaard aims to build on her previous training to initiate a novel and risky approach to study mechanisms of T-cell signaling and to bolster her controversial hypothesis that structural changes in the receptor complex are important for T-cell signaling. This award will give her the freedom to explore innovative techniques and interdisciplinary approaches that would not be supported by an R01 award.

Using a combination of novel imaging and biophysical techniques, Dr. Krogsgaard investigates how one can manipulate signaling mechanisms in T-cells which could enhance the immune response in patients with HIV or cancer or diminish T-cell activation in patients with autoimmune disease.


Contact: Jennifer Berman
NYU Langone Medical Center / New York University School of Medicine

Related biology news :

1. Blood fingerprints for cancer
2. Height linked to risk of prostate cancer development and progression
3. TGen and Washington University researchers discover new approach to treating endometrial cancer
4. Landmark study opens door to new cancer, aging treatments
5. Growth factor predicts poor outcome in breast cancer
6. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
7. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
8. Normalizing tumor vessels to improve cancer therapy
9. CSHL scientists identify new drug target against virulent type of breast cancer
10. Gene therapy anti-cancer research featured in Scientific American
11. Dense tissue promotes aggressive cancers
Post Your Comments:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions ... Melanie Aregger to serve as Chief Operating Officer. , Having joined InSphero ... team and was promoted to Head of InSphero Diagnostics in 2014. There ...
Breaking Biology Technology: